Monika Gupta, MD
Family Practice · Newark, DENPI 1073622072
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Boehringer Ingelheim at 33.2% of the total. Reporting peaked in 2019 at $74 and has fallen 51.5% since, to $36 in 2025. Among family practice clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$70
- Astellas Pharma US Inc$41
- Amgen$39
- Pfizer$17
- Novo Nordisk$15
- Lilly USA, LLC$15
- plus $13 from 1 others
What the payments were for
- Food & beverage$212100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 3 | $70 |
| Astellas Pharma US Inc | 3 | $41 |
| Amgen | 2 | $39 |
| Pfizer | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| AstraZeneca | 1 | $13 |
How this compares
$212 in reported general payments places this provider in the 95th percentile of 50 family practice providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 787 | $11,375 |
| Rosuvastatin Calcium | 423 | $9,874 |
| JanuviaSitagliptin Phosphate | 12 | $7,832 |
| Levothyroxine Sodium | 614 | $6,637 |
| Omeprazole | 248 | $4,211 |
| Pioglitazone Hcl | 119 | $3,086 |
| Simvastatin | 291 | $2,974 |
| Metformin Hcl | 366 | $2,929 |
| SynthroidLevothyroxine Sodium | 132 | $2,872 |
| Potassium Chloride | 37 | $2,644 |
| Gabapentin | 77 | $2,517 |
| Ibandronate Sodium | 54 | $2,512 |
| Esomeprazole Magnesium | 36 | $2,473 |
| Fenofibrate | 75 | $2,379 |
| Alendronate Sodium | 251 | $2,172 |
Paid to pharmacies, not to this prescriber.
Other family practice in Newark
- Temitope OlatunjiNewark$0
- Brian JanneyNewark$0
- Yvonne TingNewark$0
- Benjamin GoldenNewark$0
- Jeremy CristolNewark$0
- Amber HigginsNewark$0
- Hannah SalapehNewark$0
- Keerthi SurampudyNewark$0
- Neelam KumariNewark$0
- Neli SerafimovaNewark$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.